Opendata, web and dolomites

iProg

Tailored cell-based therapies for frontotemporal dementia and related genetically defined CNS orphan indications

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iProg project word cloud

Explore the words cloud of the iProg project. It provides you a very rough idea of what is the project "iProg" about.

desired    pgrn    progranulin    paving    treatment    neurotrophic    leverage    failing    reaching    explore    situ    drug    populations    frontotemporal    medical    suffer    safety    transforming    efficacious    patient    negligible    biologics    efficacy    severe    conduct    biotechnology    prepare    phasei    biotherapeutics    therapies    clinical    therapeutic    mutations    successful    restores    safe    modifying    lower    tech    sme    company    locally    ultimately    vision    innovation    generation    detect    market    signals    proprietary    candidates    ftd    brain    patients    right    lay    gene    implantable    standards    game    indications    sinfonia    combat    thereby    entirely    diseases    driver    disorders    cns    systemic    framework    medicine    genetically    manner    changers    solutions    iprog    unmet    orphan    neurodegenerative    iia    first    lives    exposure    disease    overcome    brd    frame    therapy    ing    instrument    degeneration    causative    repair    device    levels   

Project "iProg" data sheet

The following table provides information about the project.

Coordinator
SINFONIA BIOTHERAPEUTICS AB 

Organization address
address: HALSOVAGEN 7, NOVUM
city: HUDDINGE
postcode: 141 57
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.sinfoniabiotherapeutics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SINFONIA BIOTHERAPEUTICS AB SE (HUDDINGE) coordinator 50˙000.00

Map

 Project objective

Sinfonia Biotherapeutics is a high-tech biotechnology company. Our vision is to become a main driver in technology innovation for CNS medicine, where we lay the frame-work for entirely novel therapeutic concepts and solutions that combat the unmet medical need of severe CNS conditions, ultimately transforming patient lives. We are developing targeted therapies for genetically defined CNS orphan indications that are built on a proprietary medical device – the Brain Repair Device - that overcome several of the existing challenges associated with the failing clinical development of drug candidates for neurodegenerative diseases today. The BRD is an implantable device that allows for the in situ production of our therapeutic biologics resulting in desired CNS exposure, while the systemic exposure of the therapeutic factor is negligible. We are developing a new generation of tailored biologics for genetically defined disease/patient populations that target the disease locally in the brain. With our therapies we are thus reaching the right patient, with the right treatment, in an efficacious and safe manner. Through the SME Instrument, we will focus on further developing iProg, a novel neurotrophic therapy that restores progranulin levels in the brain of patients that suffer from frontotemporal degeneration due to mutations in the PGRN gene (FTD/PGRN), which results in lower progranulin production and is disease-causative. We will use the SME Instrument funding (Phase 1&2) to prepare and conduct PhaseI/IIa studies to explore the safety and detect the first signals of efficacy of iProg. If successful, the project will set new standards on the biologics for neurodegenerative disease market, paving a way to growth and new potential partnerships for Sinfonia. Our disease-modifying therapies have the potential to leverage an important framework for therapeutic development in neurodegenerative disorders in general and thereby to become real game changers in CNS medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPROG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPROG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More